Core Viewpoint - The company's performance in Q3 2025 aligns with expectations, showing a revenue increase but a decline in net profit due to stock incentive expenses and ongoing high R&D investments [1][2]. Financial Performance - Revenue for the first three quarters of 2025 reached 10.21 billion yuan, a year-on-year increase of 21.8% - Net profit attributable to shareholders was 810 million yuan, a year-on-year decrease of 23.8% - Adjusted net profit after stock incentive expenses was 1.18 billion yuan, a slight increase of 0.1% [1]. Development Trends - Glo Hilo is expanding steadily in Japan and Poland, with positive sales momentum in the European vaping market - The company expects to see growth in revenue from HNB products and compliant vaping products in Europe, despite regulatory challenges in the U.S. [1][2]. Short-term Profitability and R&D - Short-term profitability may be slightly pressured due to increased orders from small clients in Europe and initial sales of HNB heating devices - The company is increasing R&D investments in vaping medical and HNB new businesses, which may impact net profit in Q3 2025 [2]. Long-term Growth Prospects - The company anticipates accelerated global expansion of Glo Hilo by 2026, which is expected to drive revenue growth - The vaping medical segment is expected to commercialize, opening up long-term growth opportunities [2]. Profit Forecast and Valuation - The forecast for net profit attributable to shareholders in 2025 has been reduced by 20% to 1.05 billion yuan, while the 2026 forecast has been increased by 11% to 1.88 billion yuan - The current stock price corresponds to a 47 times P/E ratio for 2026, with a target price maintaining a 69 times P/E ratio, indicating a potential upside of 46% [2].

Core Viewpoint - The report from CICC indicates a downward adjustment of 20% in the forecast for Smoore International's (06969) 2025 net profit attributable to shareholders, bringing it to 1.05 billion yuan, while the 2026 net profit forecast is raised by 11% to 1.88 billion yuan, reflecting a positive outlook driven by HNB product sales [1] Group 1: Financial Performance - For the first three quarters of 2025, the company reported revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, while net profit attributable to shareholders was 810 million yuan, a decrease of 23.8%. Adjusted net profit after accounting for stock incentive expenses was 1.18 billion yuan, showing a slight increase of 0.1% [2] - Quarterly net profit figures for 2025 were 200 million yuan in Q1, 300 million yuan in Q2, and 317 million yuan in Q3, with year-on-year changes of -43.4%, +12.7%, and -16.4% respectively, aligning with CICC's expectations [2] Group 2: Market Expansion and Product Development - The Glo Hilo brand is expanding steadily in Japan and Poland, with the company positioned as a leader in flavor restoration, heating speed, and brand image. The positive sales momentum of heating devices is expected to contribute to revenue [3] - The company anticipates continued growth in the European vaping market, driven by differentiated compliant products from small brands, while orders in the U.S. are expected to remain stable despite regulatory tightening [3] - The company is leading in global market share for open-system proprietary brands, with expectations of continued year-on-year growth in Q3 2025 [3] Group 3: Profitability and R&D Investment - Short-term profitability may be slightly pressured due to increased orders from small customers in the European vaping market and initial sales of HNB heating devices. However, profitability is expected to improve as orders for vaping products increase and high-margin HNB products gain traction [4] - The company is increasing R&D investments in vaping medical and HNB new businesses, which, combined with the impact of stock incentive expenses, resulted in a year-on-year net profit decline of 16.4% and an adjusted net profit increase of 4% in Q3 2025 [4] Group 4: Long-term Growth Prospects - The company expects Glo Hilo to accelerate its global expansion in 2026, with concentrated shipments of HNB products likely to drive revenue growth. New products, technologies, and customers are anticipated to open up long-term opportunities [5] - In the vaping medical sector, the acceleration of complex generic drug development and the gradual realization of innovative drug collaborations are expected to lead to commercialization, providing long-term growth potential [5]

Core Viewpoint - The report from CICC indicates a downward adjustment in the net profit forecast for Smoore International (06969) for 2025 by 20% to 1.05 billion yuan, while the 2026 net profit forecast is raised by 11% to 1.88 billion yuan, reflecting a strong performance driven by HNB product sales [1] Group 1: Financial Performance - For the first three quarters of 2025, the company reported revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, while the net profit attributable to shareholders was 810 million yuan, a year-on-year decrease of 23.8% [2] - Adjusted for stock incentive expenses, the net profit attributable to shareholders was 1.18 billion yuan, showing a slight year-on-year increase of 0.1% [2] - Quarterly net profit for 1Q, 2Q, and 3Q of 2025 was 200 million, 300 million, and 317 million yuan respectively, with year-on-year changes of -43.4%, +12.7%, and -16.4% [2] Group 2: Market Expansion and Product Performance - The Glo Hilo brand is expanding steadily in Japan and Poland, with the company positioned as a leader in flavor restoration, heating speed, and brand image [3] - The company anticipates continued growth in the European vaping market, driven by differentiated compliant products amid regulatory changes [3] - The open-system self-owned brand is leading in global market share, with expectations of continued year-on-year growth in 3Q25 [3] Group 3: Cost Structure and R&D Investment - Short-term profitability is impacted by the allocation of stock incentive expenses, while R&D investments remain high [4] - The company expects slight pressure on gross margins in the short term due to increased orders from small clients in the European vaping market and initial sales of HNB heating devices [4] - The net profit and adjusted net profit for 3Q25 showed year-on-year changes of -16.4% and +4% respectively [4] Group 4: Long-term Growth Prospects - The company is optimistic about the global expansion of HNB products, which is expected to drive performance in the coming years [5] - The combination of drug-device complex generic drug development and innovative drug collaborations is anticipated to lead to commercialization in the vaping medical sector, opening up long-term growth opportunities [5]

Group 1 - The company reported Q3 2025 financial data, with revenue of 4.197 billion yuan, a year-on-year increase of 27.5%, and adjusted profit of 444 million yuan, a year-on-year increase of 4.8% [1] - HNB is expected to become a major growth driver, with significant revenue increase anticipated due to the pre-production nature and the full rollout of hilo in Japan, leading to substantial sequential growth in sales [1] - The ODM+ strategy has been further validated, with satisfactory growth from new product iterations, and overall growth expected to exceed double digits as new compliant products are launched [1] Group 2 - Emerging businesses are expected to elevate the company's valuation, with the subsidiary successfully submitting an ANDA for Breo Ellipta, which is used for asthma and COPD treatment, indicating potential for further valuation uplift [1] - The company anticipates that HNB will become a primary source of profit release by 2026, with traditional vaping business valuation solidifying [2] - Revenue projections for 2025-2027 are 14.2 billion, 16.9 billion, and 19.5 billion yuan, with corresponding net profits of 1.395 billion, 1.898 billion, and 2.368 billion yuan, leading to PE ratios of 64.53x, 47.44x, and 38.02x respectively, maintaining a "buy" rating [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company reported a significant revenue and profit increase in Q3 2025, with revenue reaching 4.197 billion yuan, a year-on-year growth of 27.5%, and adjusted profit of 444 million yuan, up 4.8% year-on-year [7] - The HNB (Heat Not Burn) segment is expected to become a major growth driver, with substantial sales growth anticipated in Japan and Europe [7] - The ODM+ strategy has shown satisfactory growth due to successful product iterations, with overall growth expected to exceed double digits [7] - The valuation of the company is expected to rise with the introduction of new compliant products and the recent FDA acceptance of a generic drug application for Breo® Ellipta® [7] - The company forecasts revenues of 14.2 billion, 16.9 billion, and 19.5 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 1.395 billion, 1.898 billion, and 2.368 billion yuan [7] Financial Performance Summary - Revenue projections for the company are as follows: 11,168 million yuan in 2023, 11,799 million yuan in 2024, 14,200 million yuan in 2025, 16,900 million yuan in 2026, and 19,500 million yuan in 2027, with a revenue growth rate of 20.35% in 2025 [6][8] - The net profit forecast shows a decline in 2024 to 1,303 million yuan, followed by a recovery to 1,395 million yuan in 2025, and further growth to 1,898 million yuan in 2026 and 2,368 million yuan in 2027 [6][8] - The company's EPS is projected to be 0.23 yuan in 2025, 0.31 yuan in 2026, and 0.38 yuan in 2027, with corresponding PE ratios of 64.53x, 47.44x, and 38.02x [6][8]

Investment Rating - The investment rating for the company is "Buy" and is maintained [12] Core Insights - Smoore International is the largest electronic vaporizer supplier globally, with growth potential unlocked by its technology positioning in HNB (Heated Not Burn) products [3][6] - The company's core business is recovering, benefiting from regulatory shifts in the industry and increasing market share among major clients [3][6] - The HNB business is expected to see significant growth, with a projected annual growth rate in the double digits and a current global penetration rate of less than 6% [3][7] Summary by Sections Introduction - Smoore International leverages its R&D advantages to launch HNB products, marking a new phase in the industry [6][17] - The company has transitioned from a pure equipment supplier to a tobacco business model, opening new growth avenues [6][17] Core Business - The HNB segment is poised for accelerated development, with a low penetration rate and high barriers to entry, indicating substantial growth potential [7][28] - The collaboration with British American Tobacco to launch Glo Hilo combines both companies' strengths, enhancing market competitiveness [7][28] Performance Outlook - The revenue-sharing model for Glo Hilo is expected to yield significant profits, with projections estimating annual profits for Smoore's HNB business to reach 6-7 billion RMB if market penetration increases [8][9] - The U.S. market presents a significant opportunity, with potential market size increases if HNB penetration rises to 15% [8][37] Traditional Business - The U.S. vaping market is expected to grow from $19.81 billion in 2021 to $27.03 billion in 2024, with a CAGR of 11% [9][20] - Regulatory changes in the U.S. are becoming more favorable, allowing for a recovery in the vaporizer business [9][20] Long-term Strategic Direction - The company is diversifying into medical and beauty vaporization, aiming for long-term growth across multiple sectors [10][19]

Core Viewpoint - The company's 1H25 performance aligns with expectations, showing revenue growth but a decline in net profit, indicating a mixed financial outlook amid evolving market conditions [1][2]. Financial Performance - Revenue for 1H25 reached 6.01 billion, an 18.3% year-on-year increase, while net profit attributable to shareholders was 500 million, a 30.8% decline. Adjusted net profit after stock incentive expenses was 740 million, down 2.1% [1]. - The company declared an interim dividend of 0.2 HKD per share, with a payout ratio of 225.1%, significantly higher than the 38.7% in 1H24, indicating increased shareholder returns [1]. Market Trends - The ToB revenue grew by 19.5% to 4.739 billion, driven by strong performance in Europe and potential improvements in the U.S. market due to stricter regulations [1]. - In Europe, revenue surged by 38% to 2.73 billion, benefiting from regulatory changes that favored compliant companies [1]. - U.S. revenue increased by 1.5% to 1.89 billion, with expectations of continued improvement as enforcement tightens [1]. - Domestic revenue, however, saw a decline of 6.1% to 120 million [1]. Product Development - The ToC revenue rose by 14.1% to 1.274 billion, with significant growth in the APV segment, particularly in Europe, where new product launches are driving user conversion [2]. - The APV revenue in Europe and the U.S. was 1.07 billion and 170 million, respectively, with declines of 15.1% and 6.7% [2]. - The nebulization beauty segment experienced a remarkable growth of 2595% to 30.618 million, with over 10,000 C-end users and more than 100 B-end partnerships established [2]. Profitability and Costs - The overall gross margin remained stable, decreasing slightly by 0.5 percentage points to 37.3%. However, the net profit margin fell by 5.9 percentage points to 8.3%, and adjusted for stock incentive expenses, it decreased by 1.2 percentage points to 12.3% [2]. - Sales expense ratio increased by 0.8 percentage points to 8.2% due to heightened investment in self-owned brands, while R&D expense ratio decreased by 2.9 percentage points to 12% [2]. - Management expenses rose significantly by 15.5 percentage points to 22.2%, primarily due to increased stock incentive costs [2]. Growth Outlook - The HNB segment is expected to accelerate globally, with Glo Hilo's market share in Japan increasing by 1.5% during its sales period, indicating strong growth potential [3]. - The regulatory environment for vaping products in Europe and the U.S. is expected to lead to a more standardized industry, allowing the company to recover market share and continue growing [3]. - The company is also focusing on developing nebulization medical products and expanding its nebulization beauty segment domestically, which opens up additional growth opportunities [3]. Profit Forecast and Valuation - The company maintains its profit forecast and industry outperform rating, with a target price reflecting a 4% upside from the current stock price [3].

Core Viewpoint - Zheshang Securities maintains a "Buy" rating for Smoore International (06969.HK), highlighting the favorable regulatory environment for HNB products compared to vaping products, which is expected to accelerate market penetration [1] Group 1: Market Position and Competitive Landscape - The competitive landscape for HNB products is more favorable than that for vaping products, suggesting a better market position for Smoore International [1] - The product experience of HNB is improving, which is anticipated to enhance penetration rates [1] Group 2: Future Growth Projections - Smoore International is expected to achieve revenues of 12.89 billion, 15.31 billion, and 18.35 billion from 2025 to 2027 [1] - The projected net profit attributable to the parent company is forecasted to be 1.32 billion, 2.00 billion, and 2.73 billion for the same period [1] Group 3: Strategic Developments - The launch of British American Tobacco's new generation GloHilo product in Japan on September 1 is expected to benefit Smoore International as a core supplier [1] - The medical business is identified as the next important growth area for Smoore International [1]

Investment Rating - The industry investment rating is "Overweight (Maintain)" [1] Core Insights - The report highlights the potential growth in the HNB (Heated Not Burned) market, particularly with the launch of Glo Hilo in Japan, which is expected to enhance sales performance and accelerate market penetration [4][5] - The report indicates that British American Tobacco's (BAT) revenue for the first half of 2025 is projected to grow by 1%-2%, driven by strong performance in the U.S. market despite an overall decline in industry retail sales [5] - The report emphasizes the importance of technological barriers in the HNB product segment, particularly in heating technology and flavoring processes, which are crucial for enhancing user experience [4] Industry Performance Over the Last Twelve Months - The industry has shown a relative return of 4.33% over the past month, 4.58% over the past three months, and 5.82% over the past twelve months compared to the CSI 300 index [2] - Absolute returns for the same periods are 4.83%, 2.59%, and 13.97% respectively [2] Related Research Reports - Previous reports include insights on the light industry manufacturing sector and the anticipated release of new products in the smart glasses market [3] - The report also references the performance outlook for British American Tobacco in the first half of 2025, focusing on new product launches and market strategies [5]